GlassScriptPrepare for your visit
Cavan Quam
Family · Sacramento, CA · NPI 1801630058
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$671.50
in general payments reported to CMS, 2019-2025 · $530 in 2025
The $530 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Who reported paying
General payments only, top 6 by amount.
- Astrazeneca Pharmaceuticals LP $126.86
- Novo Nordisk INC $80.28
- Amgen INC. $77.57
- Abbvie INC. $70.74
- Exact Sciences Corporation $70.53
- Glaxosmithkline, LLC. $55.05
Drugs and devices associated with these payments
Airsupra Ozempic Ubrelvy Qulipta Rybelsus Trelegy Ellipta Repatha Otezla Mounjaro Breztri The Cologuard Plus Collection Kit Kerendia
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Cavan Quam listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/11607389/cavan-quam